Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 22; no. 3; pp. 381 - 388
• Main Authors: Kavakli, K., Smith, L., Kuliczkowski, K., Korth-Bradley, J., You, C. W., Fuiman, J., Zupančić-Šalek, S., Abdul Karim, F., Rendo, P.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.05.2016; Wiley Subscription Services, Inc
• Subjects: Adolescent; Adult; Aged; BeneFIX; Bleeding; Child; Coagulants - adverse effects; Coagulants - therapeutic use; Coagulation factors; Dosage; Drug Administration Schedule; factor IX; Factor IX - genetics; Factor IX - metabolism; Factor IX - therapeutic use; Factor IX deficiency; haemophilia B; Hemophilia; Hemophilia B - drug therapy; Hemorrhage - epidemiology; Hemorrhage - prevention & control; Humans; Male; Middle Aged; pharmacokinetics; prevention; Prophylaxis; Recombinant Proteins - biosynthesis; Recombinant Proteins - genetics; Recombinant Proteins - therapeutic use; safety; Thrombosis - etiology; Treatment Outcome; Young Adult; pharmacokinetics; factor IX; haemophilia B; BeneFIX; safety; prevention

Introduction Limited data are available on optimal prophylaxis regimens of factor IX (FIX) replacements for patients with haemophilia B. Aim This multicentre, open‐label study evaluated the efficacy and safety of once‐weekly prophylaxis with nonacog alfa compared with on‐demand treatment in adolesce...